For those who don’t benefit from modulators, the fight against CF can feel isolating and uncertain. Five members of our community share how they’ve transformed their personal struggles into purpose — ...

Shares of Ventyx Biosciences VTYX have skyrocketed 156% in the past month. The massive surge in the stock price was primarily ...

Kangpu Biopharmaceuticals announced today that the company will deliver a poster presentation to highlight the Phase I ...

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated ...

More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from ...

Discover how drug development targeting ion channels could be transformed with a new technique using nuclear magnetic ...

There was a wonderful atmosphere in the Martello, Bray, on Friday, November 14, as local women came together for a ladies’ lunch in aid of Cystic Fibrosis Ireland. The event was organised by Afric ...

(Z)-Endoxifen is Atossa's investigational ER-modulating small molecule. In oncology and CNS studies to date, (Z)-endoxifen has shown a favorable safety profile and pharmacology distinct from tamoxifen ...

ART-501, formerly known as ARD-501 or TLX-032 for Tulex, is a proprietary oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug developed through a ...

AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM” or the 'Company”), today provided a business update and reported its ...